Earnings Scheduled For March 6, 2023
Companies Reporting Before The Bell
• Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter.
Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $11
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $18 to $11.
Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder
Passage Bio Inc (NASDAQ:PASG) announced new interim safety, biomarker, and clinical development results from cohorts 1-3 in the Imagine-1 Phase…
Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $11
Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $13 to $11.
Citigroup Maintains Buy on Passage Bio, Lowers Price Target to $5
Citigroup analyst Neena Bitritto-Garg maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $7 to $5.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 184 companies set new 52-week lows.
Canaccord Genuity Initiates Coverage On Passage Bio with Buy Rating, Announces Price Target of $8
Canaccord Genuity analyst Whitney Ijem initiates coverage on Passage Bio (NASDAQ:PASG) with a Buy rating and announces Price Target of $8.
